Technical Analysis for MYL - Mylan Inc.

Grade Last Price % Change Price Change
grade F 18.52 -2.01% -0.38
MYL closed down 2.01 percent on Monday, October 14, 2019, on 74 percent of normal volume.

Earnings due: Nov 4

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical MYL trend table...

Date Alert Name Type % Chg
Oversold Stochastic Weakness 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.01%
Stochastic Buy Signal Bullish -2.01%
Up 3 Days in a Row Strength -2.01%
Oversold Stochastic Weakness -2.01%
Outside Day Range Expansion 0.27%
Oversold Stochastic Weakness 0.27%
Narrow Range Bar Range Contraction 0.49%
NR7 Range Contraction 0.49%
NR7-2 Range Contraction 0.49%

Older signals for MYL ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Mylan Inc. engages in the development, manufacture, marketing, licensing, and distribution of generic and branded generic pharmaceuticals, specialty pharmaceuticals, and active pharmaceutical ingredients (APIs) worldwide. It operates in two segments, Generics and Specialty. The Generics segment primarily develops, manufactures, sells, and distributes generic or branded generic pharmaceutical products in tablet, capsule, and injectable or transdermal patch forms, as well as API. It also focuses on developing APIs with non-infringing processes to partner with manufacturers. This segment serves proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The Specialty segment manufactures and sells branded specialty injectable, nebulized, and transdermal products for life-threatening conditions. Its products include EpiPen Auto-Injector to treat severe allergic reactions; and Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients. This segment serves pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. The company also manufactures and sells injectable products in various therapeutic areas for the hospital setting; supplies APIs for the manufacture of antiretroviral (ARV) drugs to treat HIV/AIDS; offers finished dosage form (FDF) products in the ARV market; and manufactures non-ARV FDF products, as well as focuses on developing, manufacturing, and commercializing dry powder inhaler delivery platform. Mylan Inc. has a strategic collaboration with Pfizer Japan Inc. The company was formerly known as Mylan Laboratories Inc. and changed its name to Mylan Inc. in October 2007. Mylan Inc. was founded in 1961 and is based in Canonsburg, Pennsylvania.
Health Life Sciences Pharmaceutical Industry Pharmaceuticals Pharmaceutical Industry In China Pharmaceuticals Policy Active Pharmaceutical Ingredients HIV/Aids Generic Drug Healthcare Institutions Disorder Generic Pharmaceutical Products Pharmaceutical Wholesalers Drug Manufacturers Injectable Products
Is MYL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 37.56
52 Week Low 16.63
Average Volume 5,454,548
200-Day Moving Average 23.3423
50-Day Moving Average 19.612
20-Day Moving Average 19.555
10-Day Moving Average 18.664
Average True Range 0.708
ADX 17.23
+DI 18.4247
-DI 22.0965
Chandelier Exit (Long, 3 ATRs ) 20.776
Chandelier Exit (Short, 3 ATRs ) 20.224
Upper Bollinger Band 21.6229
Lower Bollinger Band 17.4871
Percent B (%b) 0.25
BandWidth 21.149578
MACD Line -0.4549
MACD Signal Line -0.3295
MACD Histogram -0.1253
Fundamentals Value
Market Cap 9.93 Billion
Num Shares 536 Million
EPS 1.24
Price-to-Earnings (P/E) Ratio 14.94
Price-to-Sales 1.72
Price-to-Book 1.61
PEG Ratio 1.59
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.21
Resistance 3 (R3) 19.26 19.08 19.10
Resistance 2 (R2) 19.08 18.90 19.06 19.06
Resistance 1 (R1) 18.80 18.80 18.71 18.75 19.02
Pivot Point 18.62 18.62 18.58 18.60 18.62
Support 1 (S1) 18.34 18.44 18.25 18.29 18.02
Support 2 (S2) 18.16 18.34 18.14 17.98
Support 3 (S3) 17.88 18.16 17.95
Support 4 (S4) 17.83